Plain-English translation of NCT07616401 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research study is looking for early warning signs in your blood that can predict how well you'll respond to bone-strengthening medications. Researchers will compare two treatments — romosozumab and abaloparatide — in postmenopausal women with osteoporosis. By studying special markers in your blood, they hope to figure out which medication will work best for each person before starting treatment.
Osteoporosis weakens bones and increases fracture risk, especially in postmenopausal women. While several medications can help strengthen bones, doctors don't yet have a reliable way to predict which medication will work best for each patient. This study aims to find blood-based markers that can guide treatment selection and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would be assigned to take one of two bone-strengthening medications for 12 months while researchers monitor your response. This involves regular visits where your bone density will be measured with a scan, and blood samples will be drawn to look for markers that predict how well the medication is working for you. The study aims to create a personalized profile of your treatment response using these blood tests.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy